Manzanilla-García HA, Maldonado-Ávila M, Aguilar-Barradas J, Lira-Dale A

Idioma: Español
Referencias bibliográficas: 49
Paginas: 307-313
Archivo PDF: 316.08 Kb.

RESUMEN

El cáncer de vejiga es la segunda causa más común de cáncer en el tracto urinario. El tipo histológico más frecuente es el carcinoma de células transicionales (CCT). Alrededor de 70% de estas malformaciones es superficial (sin evidencia de invasión muscular), carcinoma in situ (Tis), Ta y T1. El comportamiento biológico de estos tumores es variable, desde escasa tendencia a recurrir hasta un alto grado de recurrencia y progresión. Aunque el tratamiento estándar lo constituye la resección transuretral del tumor de vejiga (RTUTV), se ha establecido una gran cantidad de medidas complementarias basadas en la administración de diferentes agentes intravesicales, por ejemplo los agentes quimioterapéuticos y la inmunoterapia, como el bacilo de Calmette-Guérin (BCG), sin determinar aún cuál es el más apropiado. En este artículo se presenta una revisión del uso del BCG en el carcinoma superficial de vejiga, indicaciones, mecanismo de acción, contraindicaciones y diferentes resultados en sus distintas etapas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Razack AHA. Bacillus Calmette-Guérin and Bladder Cancer. Asian J Surg 2007; 30 (4): 302-309.

2. Babjuk M, Oosterlinck W, Sylvester R, et al. Guía clínica del carcinoma urotelial no músculo invasivo de la Asociación Europea de Urología. Actas Urol Esp 2009; 33 (4): 361-371.

3. Davis JW, Sheth SI, Doviak MJ, et. al. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10 –year follow-up. J Urol 2002; 167: 494-501.

4. Lockyer CRW, Gillat DA. BCG immunotherapy for superficial bladder cancer. J R Soc Med 2001; 94: 119-123.

5. Jemal A, Siegel R, Ward E, et. al., Cancer Statistics 2008. CA Cancer J Clin 2008; 58 (2): 71-96.

6. Messing EM, Vaillancourt A. Hematuria screening for bladder cancer. J Occup Med1990; 32 (9): 838-845.

7. Fernández-Cañabate E, Longoni-Merino M. Infección sistémica secundaria a instalación vesical con BCG. Farm Hosp 2006; 30: 313-323.

8. Meyer JP, Persad R, Gillatt DA. Use of bacille Calmette-Guérin in superficial bladder cancer. Postgrad Med J 2002; 78: 449-454.

9. Bohle A, Jocham D. Intravesical Immunotherapy with Bacillus Calmette- Guérin. 1st. English Edition. Urban & Fischer; 2000.

10. Merz VW, Marth D, Kraft R, et al. Analysis of early failures after intravesical installation therapy with BCG for carcinoma in situ of the bladder. Br J Urol 1995; 75: 180-184.

11. Lamm DL. Long term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19: 573-580.

12. Holmgren I. La tuberculine et le BCG chez les cancéreux. Schweiz. Med. Wochenschr 1935, 65: 1203-1206.

13. Coe JE, Feldman JD. Extracutaneous delayed hypersensitivity, particularly in the guinea pig bladder. Immunol 1966; 10:127-136.

14. Morton DL, Holmes EC, Eilber FR. Immunological aspects of neoplasia: a rational basis for immunotherapy. Ann Intern Med 1971; 74 (4): 587-604.

15. Zbar B, Bernstein ID, Rapp HJ. Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst 1971; 46 (4): 831-839.

16. Zbar B, Rapp HJ. Immunotherapy of guinea pig cancer with BCG. Cancer 1974; 34: 1532-1540.

17. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette- Guérin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-183.

18. Elkabani M, Greene NJ, Vincent LA, et al. Disseminated mycobacterium bovis after BCG treatments for bladder cancer. Cancer Control 2000; 7 (5): 476-481.

19. Shamhart DH, de Boer EC, de Reijke, et al. Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: their practical use. Eur Urol 2000; 37(Suppl): 16-23.

20. Ratliff TL, McGarr JA, Abou-Zeid C, et. al. Attachment of mycobacteria to fibronectin-coated surfaces. J Gen Microbiol 1988; 134 (5): 1307-1313.

21. Nogueira-March JL, Ojea-Calvo A, Rodríguez-Iglesias F, et. al. Indicaciones de la BCG en los tumores superficiales de vejiga. Actas Urol Esp 1999; 23(8):643-656.

22. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003; 170(3): 964-969.

23. Ratliff TL, Kavoussi LR, Catalona WJ. Role of fibronectin in intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 1988; 139: 410-414.

24. Ratliff TL, Hudson MA, Catalona WJ. Strategy for improving therapy of superficial bladder cancer. World J Urol 1991; 9: 95-98.

25. Manoharan M, Soloway MS. Optimal management of the T1G3 bladder cancer. Urol Clin N Am 2005; 32: 133-145.

26. Duque JLF, Loughlin KR. An overview of the treatment of superficial bladder cancer. Urol Clin N Am 2000; 27 (1): 125-135.

27. Peyromaure M, Guerin F, Amsellem-Ouazana D, et al. Intravesical BCG therapy for stageT1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J Urol 2003; 169 (6): 2110-2112.

28. Mugiya S, Ozono S, Nagata M. Long term outcome of a low dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG. Jpn J Clin Oncol 2005; 35 (7): 395-399.

29. Dalbagni G, Herr HW. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin N Am 2000; 27 (1): 137-146.

30. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178(6):2314-2330.

31. Akaza H. BCG treatment of existing Ta, T1 tumors or carcinoma in situ of the bladder. Eur Urol 1995; 27(Suppl 1):9–12.

32. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal metaanalysis of comparative studies on recurrence and toxicity. J Urol 2003; 169 (1): 90-95.

33. Sylvester RJ, van der Meijden AP, Witjes JA, et. al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005; 174 (1): 86-91.

34. Shahin O, Thalmann GN, Rentsch C, et al. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guérin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003; 169(1):96-100.

35. Solsona E, Iborra I, Dumont R, et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 1999; 164(3 Pt 1):685–689.

36. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168 (5): 1964-1970.

37. Peyromaure M, Guerin F, Amsellem-Ouazana D, et. al. Intravesical BCG therapy for stageT1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J Urol 2003; 169(6): 2110-2112.

38. Sylvester RJ, van der Meijden AP, Witjes JA, et al. Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005; 174(1): 86-91.

39. Griffiths TR, Charlton M, Neal DE, et. al. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002; 167 (6): 2408-2412.

40. Jones JS, Campbell SC. Non-muscle-invasive bladder cancer (Ta, T1, and CIS) Campbell´s Urology. 9th Edition, Saunders W B Co, Dec 2006: 2447-2467.

41. Rozenblit A, Wasserman E, Marin ML, et. al. Infected Aortic Aneurysm and vertebral osteomyelitis after intravesical bacillus Calmette- Guérin therapy. AJR AM J Roentgenol 1996 ; 167(3): 711-713.

42. Rabe J, Neff KW, Lehmann KJ, et. al. Milliary Tuberculosis after intravesical bacilli Calmette-Guérin immunotherapy for bladder cancer. AJR AM J Roentgenol 1999; 172(3):748-750.

43. Frech CG, Hickey L, Bell DG. Caseating granulomas on the glans penis as a complication of bacilli Calmette-Guérin intravesical therapy. Rev Urol 2001; 3(1): 36-38.

44. Leebeek FWG, Ouwndijk RJ, Kolk AHJ, et. al. Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation. Gut 1996; 38: 616-618.

45. Senés AT, Badet L, Lyonnet D, et al. Ganulomatous renal masses following intravesical bacillus Calmette Guérin therapy: the central unaffected calyx sign. Br J Radiol 2007; 80 (958): 230-233.

46. Diner EK, Verghese M. Interstitial pneumonitis secondary to intravesical bacillus Calmette-Guérin for carcinoma in-situ of the bladder. Int Braz J Urol 2004; 30(5):400-402.

47. Abu-Nader R, Terrell CL. Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical BCG use. Mayo Clin Proc 2002; 77(4):393-397.

48. Rawls WH, Lamm DL, Lowe BA, et al. Fatal sepsis following intravesical bacillus Calmette-Guérin administration for bladder cancer. J Urol 1990;144(6):1328-1330.

49. Deresiewicz RL, Stone RM, Aster JC. Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guérin. J Urol 1990; 144(6):1331-1333.